Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia

Roberto Mota, Jessica E. Rodríguez, Andrea Bonetto, Thomas M. O'Connell, Scott A. Asher, Traci L. Parry, Pamela Lockyer, Christopher R. McCudden, Marion E. Couch, Monte Willis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cancer cachexia is a severe wasting syndrome characterized by the progressive loss of lean body mass and systemic inflammation. Up to 80% of cancer patients experience cachexia, with 20-30% of cancer-related deaths directly linked to cachexia. Despite efforts to identify early cachexia and cancer relapse, clinically useful markers are lacking. Recently, we identified the role of muscle-specific ubiquitin ligases Atrogin-1 (MAFbx, FBXO32) and Muscle Ring Finger-1 in the pathogenesis of cardiac atrophy and hypertrophy. We hypothesized that during cachexia, the Atrogin-1 and MuRF1 ubiquitin ligases are released from muscle and migrate to the circulation where they could be detected and serve as a cachexia biomarker. To test this, we induced cachexia in mice using the C26 adenocarcinoma cells or vehicle (control). Body weight, tumor volume, and food consumption were measured from inoculation until ~day 14 to document cachexia. Western blot analysis of serum identified the presence of Atrogin-1 and MuRF1 with unique post-translational modifications consistent with mono- and poly- ubiquitination of Atrogin-1 and MuRF1 found only in cachectic serum. These findings suggest that both increased Atrogin-1 and the presence of unique post-translational modifications may serve as a surrogate marker specific for cachexia.

Original languageEnglish (US)
Pages (from-to)1948-1958
Number of pages11
JournalAmerican Journal of Cancer Research
Volume7
Issue number9
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Cachexia
Ligases
Ubiquitin
Biomarkers
Muscles
Neoplasms
Post Translational Protein Processing
Wasting Syndrome
Ubiquitination
Cardiomegaly
Tumor Burden
Serum
Fingers
Atrophy
Adenocarcinoma
Western Blotting
Body Weight
Inflammation
Recurrence
Food

Keywords

  • Atrogin-1
  • Biomarkers
  • Cancer cachexia
  • FBXO32
  • Muscle ring Finger-1
  • TRIM63

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mota, R., Rodríguez, J. E., Bonetto, A., O'Connell, T. M., Asher, S. A., Parry, T. L., ... Willis, M. (2017). Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia. American Journal of Cancer Research, 7(9), 1948-1958.

Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia. / Mota, Roberto; Rodríguez, Jessica E.; Bonetto, Andrea; O'Connell, Thomas M.; Asher, Scott A.; Parry, Traci L.; Lockyer, Pamela; McCudden, Christopher R.; Couch, Marion E.; Willis, Monte.

In: American Journal of Cancer Research, Vol. 7, No. 9, 01.01.2017, p. 1948-1958.

Research output: Contribution to journalArticle

Mota, R, Rodríguez, JE, Bonetto, A, O'Connell, TM, Asher, SA, Parry, TL, Lockyer, P, McCudden, CR, Couch, ME & Willis, M 2017, 'Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia', American Journal of Cancer Research, vol. 7, no. 9, pp. 1948-1958.
Mota R, Rodríguez JE, Bonetto A, O'Connell TM, Asher SA, Parry TL et al. Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia. American Journal of Cancer Research. 2017 Jan 1;7(9):1948-1958.
Mota, Roberto ; Rodríguez, Jessica E. ; Bonetto, Andrea ; O'Connell, Thomas M. ; Asher, Scott A. ; Parry, Traci L. ; Lockyer, Pamela ; McCudden, Christopher R. ; Couch, Marion E. ; Willis, Monte. / Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia. In: American Journal of Cancer Research. 2017 ; Vol. 7, No. 9. pp. 1948-1958.
@article{a89ffb6700d5496faad0c0e0061813be,
title = "Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia",
abstract = "Cancer cachexia is a severe wasting syndrome characterized by the progressive loss of lean body mass and systemic inflammation. Up to 80{\%} of cancer patients experience cachexia, with 20-30{\%} of cancer-related deaths directly linked to cachexia. Despite efforts to identify early cachexia and cancer relapse, clinically useful markers are lacking. Recently, we identified the role of muscle-specific ubiquitin ligases Atrogin-1 (MAFbx, FBXO32) and Muscle Ring Finger-1 in the pathogenesis of cardiac atrophy and hypertrophy. We hypothesized that during cachexia, the Atrogin-1 and MuRF1 ubiquitin ligases are released from muscle and migrate to the circulation where they could be detected and serve as a cachexia biomarker. To test this, we induced cachexia in mice using the C26 adenocarcinoma cells or vehicle (control). Body weight, tumor volume, and food consumption were measured from inoculation until ~day 14 to document cachexia. Western blot analysis of serum identified the presence of Atrogin-1 and MuRF1 with unique post-translational modifications consistent with mono- and poly- ubiquitination of Atrogin-1 and MuRF1 found only in cachectic serum. These findings suggest that both increased Atrogin-1 and the presence of unique post-translational modifications may serve as a surrogate marker specific for cachexia.",
keywords = "Atrogin-1, Biomarkers, Cancer cachexia, FBXO32, Muscle ring Finger-1, TRIM63",
author = "Roberto Mota and Rodr{\'i}guez, {Jessica E.} and Andrea Bonetto and O'Connell, {Thomas M.} and Asher, {Scott A.} and Parry, {Traci L.} and Pamela Lockyer and McCudden, {Christopher R.} and Couch, {Marion E.} and Monte Willis",
year = "2017",
month = "1",
day = "1",
language = "English (US)",
volume = "7",
pages = "1948--1958",
journal = "American Journal of Cancer Research",
issn = "2156-6976",
publisher = "e-Century Publishing Corporation",
number = "9",

}

TY - JOUR

T1 - Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia

AU - Mota, Roberto

AU - Rodríguez, Jessica E.

AU - Bonetto, Andrea

AU - O'Connell, Thomas M.

AU - Asher, Scott A.

AU - Parry, Traci L.

AU - Lockyer, Pamela

AU - McCudden, Christopher R.

AU - Couch, Marion E.

AU - Willis, Monte

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Cancer cachexia is a severe wasting syndrome characterized by the progressive loss of lean body mass and systemic inflammation. Up to 80% of cancer patients experience cachexia, with 20-30% of cancer-related deaths directly linked to cachexia. Despite efforts to identify early cachexia and cancer relapse, clinically useful markers are lacking. Recently, we identified the role of muscle-specific ubiquitin ligases Atrogin-1 (MAFbx, FBXO32) and Muscle Ring Finger-1 in the pathogenesis of cardiac atrophy and hypertrophy. We hypothesized that during cachexia, the Atrogin-1 and MuRF1 ubiquitin ligases are released from muscle and migrate to the circulation where they could be detected and serve as a cachexia biomarker. To test this, we induced cachexia in mice using the C26 adenocarcinoma cells or vehicle (control). Body weight, tumor volume, and food consumption were measured from inoculation until ~day 14 to document cachexia. Western blot analysis of serum identified the presence of Atrogin-1 and MuRF1 with unique post-translational modifications consistent with mono- and poly- ubiquitination of Atrogin-1 and MuRF1 found only in cachectic serum. These findings suggest that both increased Atrogin-1 and the presence of unique post-translational modifications may serve as a surrogate marker specific for cachexia.

AB - Cancer cachexia is a severe wasting syndrome characterized by the progressive loss of lean body mass and systemic inflammation. Up to 80% of cancer patients experience cachexia, with 20-30% of cancer-related deaths directly linked to cachexia. Despite efforts to identify early cachexia and cancer relapse, clinically useful markers are lacking. Recently, we identified the role of muscle-specific ubiquitin ligases Atrogin-1 (MAFbx, FBXO32) and Muscle Ring Finger-1 in the pathogenesis of cardiac atrophy and hypertrophy. We hypothesized that during cachexia, the Atrogin-1 and MuRF1 ubiquitin ligases are released from muscle and migrate to the circulation where they could be detected and serve as a cachexia biomarker. To test this, we induced cachexia in mice using the C26 adenocarcinoma cells or vehicle (control). Body weight, tumor volume, and food consumption were measured from inoculation until ~day 14 to document cachexia. Western blot analysis of serum identified the presence of Atrogin-1 and MuRF1 with unique post-translational modifications consistent with mono- and poly- ubiquitination of Atrogin-1 and MuRF1 found only in cachectic serum. These findings suggest that both increased Atrogin-1 and the presence of unique post-translational modifications may serve as a surrogate marker specific for cachexia.

KW - Atrogin-1

KW - Biomarkers

KW - Cancer cachexia

KW - FBXO32

KW - Muscle ring Finger-1

KW - TRIM63

UR - http://www.scopus.com/inward/record.url?scp=85030626743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030626743&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85030626743

VL - 7

SP - 1948

EP - 1958

JO - American Journal of Cancer Research

JF - American Journal of Cancer Research

SN - 2156-6976

IS - 9

ER -